141 related articles for article (PubMed ID: 24276245)
21. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
Tiwari AK; Sodani K; Wang SR; Kuang YH; Ashby CR; Chen X; Chen ZS
Biochem Pharmacol; 2009 Jul; 78(2):153-61. PubMed ID: 19427995
[TBL] [Abstract][Full Text] [Related]
22. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
23. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.
Ejendal KF; Hrycyna CA
Curr Protein Pept Sci; 2002 Oct; 3(5):503-11. PubMed ID: 12369998
[TBL] [Abstract][Full Text] [Related]
24. Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate.
Wang L; Liu L; Chen Y; Du Y; Wang J; Liu J
Pathol Res Pract; 2018 Sep; 214(9):1467-1473. PubMed ID: 30104076
[TBL] [Abstract][Full Text] [Related]
25. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
Lemos C; Jansen G; Peters GJ
Br J Cancer; 2008 Mar; 98(5):857-62. PubMed ID: 18253130
[TBL] [Abstract][Full Text] [Related]
26. ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling.
Vesel M; Rapp J; Feller D; Kiss E; Jaromi L; Meggyes M; Miskei G; Duga B; Smuk G; Laszlo T; Karner I; Pongracz JE
Respir Res; 2017 Mar; 18(1):52. PubMed ID: 28340578
[TBL] [Abstract][Full Text] [Related]
27. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
Zhang Y; Laterra J; Pomper MG
Neoplasia; 2009 Jan; 11(1):96-101. PubMed ID: 19107236
[TBL] [Abstract][Full Text] [Related]
28. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
29. Characterization of a Potent, Selective, and Safe Inhibitor, Ac15(Az8)
Chong TC; Wong ILK; Cui J; Law MC; Zhu X; Hu X; Kan JWY; Yan CSW; Chan TH; Chow LMC
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362047
[TBL] [Abstract][Full Text] [Related]
30. Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.
Wang F; Mi YJ; Chen XG; Wu XP; Liu Z; Chen SP; Liang YJ; Cheng C; To KK; Fu LW
Mol Med; 2012 Jul; 18(1):887-98. PubMed ID: 22549112
[TBL] [Abstract][Full Text] [Related]
31. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.
Haimeur A; Conseil G; Deeley RG; Cole SP
Curr Drug Metab; 2004 Feb; 5(1):21-53. PubMed ID: 14965249
[TBL] [Abstract][Full Text] [Related]
32. WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells.
Zhang H; Zhang YK; Wang YJ; Kathawala RJ; Patel A; Zhu H; Sodani K; Talele TT; Ambudkar SV; Chen ZS; Fu LW
Cancer Sci; 2014 Aug; 105(8):1071-8. PubMed ID: 24903205
[TBL] [Abstract][Full Text] [Related]
33. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
Ni Z; Bikadi Z; Rosenberg MF; Mao Q
Curr Drug Metab; 2010 Sep; 11(7):603-17. PubMed ID: 20812902
[TBL] [Abstract][Full Text] [Related]
34. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
Wang XK; To KK; Huang LY; Xu JH; Yang K; Wang F; Huang ZC; Ye S; Fu LW
Oncotarget; 2014 Dec; 5(23):11971-85. PubMed ID: 25436978
[TBL] [Abstract][Full Text] [Related]
35. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
36. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
Hasanabady MH; Kalalinia F
J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991
[TBL] [Abstract][Full Text] [Related]
37. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
38. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
Sun Z; Zhao Z; Li G; Dong S; Huang Z; Ye L; Liang H; Qu J; Ai X; Zhang W; Chen X
Tumori; 2010; 96(1):90-6. PubMed ID: 20437864
[TBL] [Abstract][Full Text] [Related]
39. Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.
Kalalinia F; Elahian F; Behravan J
J Cancer Res Clin Oncol; 2011 Feb; 137(2):321-30. PubMed ID: 20422426
[TBL] [Abstract][Full Text] [Related]
40. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
